Globetech Environmental, Inc. Form 10QSB March 14, 2008 UNITED STATES	
SECURITIES AND EXCHANGE COMMISSION	
Washington, DC 20549	
FORM 10-QSB	
(Mark One)	
X QUARTERLY REPORT UNDER SECTION 13 OR 15(d)	OF THE SECURITIES AND EXCHANGE ACT OF 1934
For the quarterly period ended Septem	ber 30, 2007
OR	
[] TRANSITION REPORT PURSUANT TO SECTION 13 O	R 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to	
Commission File Number 0-27737	
GLOBETECH ENVIRONMENTAL, INC.	
(Exact name of small business issuer as specified in its charter)	
Nevada (State or other jurisdiction of incorporation or organization)	77-0454856 (IRS Employer Identification No.)
#700-300 South Fourth Street, Las Vegas, Nevada 89101	
(Address of principal executive offices)(Zip Code)	
(403) 261-2929	

(Registrant's telephone number, including area code)			
(Former name, former address and former fiscal year, if changed since last report)			
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to such filing requirements for the past 90 days. Yes X No []			
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the E	xchange A	act. Yes o	o No x
As of the December 31, 2007, we had 68,785,437 shares of Common Stock outstanding.			
Transitional Small Business Disclosure Format (check one)	Yes []	No X

GLOBETECH ENVIRONMENTAL, INC.

FORM 10-QSB

INDEX

PART I.	FINANCIAL INFORMATION	Page No.
	Item 1. Financial Statements (Unaudited)	
	Balance Sheets as of September 30, 2007 and December 31, 2006	3
	Statements of Operations and Comprehensive Loss for the three months ended September 30, 2007 and September 30, 2006	4
	Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2007 and September 30, 2006	5
	Statements of Cash Flows for the nine months Ended September 30, 2007 and September 30, 2006	ϵ
	Notes to Financial Statements	7
	Item 2. Management's Discussion and Analysis of Plan of Operations Item 3. Controls and Procedures	11 14
PART II	OTHER INFORMATION	
	Item 6 Exhibits	14

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

GLOBETECH ENVIRONMENTAL, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

Current assets			September 30, 2007			December 31, 2006	,	
Cash and cash equivalents \$ 534,126 \$ 71,628 Prepaid and advances 494,089 11,546 Other 171,481 49,256 Accounts receivable 52,480 10,316 Total current assets 1,252,176 142,746 Tangible assets 847,821 113,129 Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets \$ 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit **** Current liabilities** **** Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 *** Due to related party - 72,862 *** Demand notes payable - 171,233 *** Bank line of credit - 134,035 *** Capital lease payable 661,559 - 17,481 Total current liabilities 2,433,927 1,595,142 *** Due to stockholders 2,175,000 - *** Stockholders et al	Assets		(unaudited)					
Prepaid and advances 494,089 11,546 Other 171,481 49,256 Accounts receivable 52,480 10,316 Total current assets 1,252,176 142,746 Tangible assets 847,821 113,129 Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit Total Assets \$ 502,531 Current liabilities 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 134,035 Due to stockholders' - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revnue 2,175,000 - Deferred gain 366,293 - <								
Other 171,481 49,256 Accounts receivable 52,480 10,316 Total current assets 1,252,176 142,746 Tangible assets 847,821 113,129 Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets \$ 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit Current liabilities Accounts payable and accrued liabilities 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: 68,03	Cash and cash equivalents	\$	534,126		\$	71,628		
Accounts receivable	*		494,089			,		
Total current assets 1,252,176 142,746 Tangible assets 847,821 113,129 Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets \$ 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 171,233 Bank line of credit - 171,233 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: 88,035 59,061 Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital <	Other		171,481					
Tangible assets 847,821 113,129 Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets \$ 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: 68,035 59,061 Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,	Accounts receivable		52,480			10,316		
Intangible property - patents and licenses 1,290,017 1,286,840 Total Assets \$ 3,390,014 \$ 1,542,715 Total Intangible property - patents and Stockholders' Deficit Substitution Substitu	Total current assets		1,252,176			142,746		
Total Assets \$ 3,390,014 \$ 1,542,715 Liabilities and Stockholders' Deficit Current liabilities: \$ 740,275 \$ 502,531 Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: - - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 - Retained deficit (1,650,608) (273,432)	Tangible assets		847,821			113,129		
Liabilities and Stockholders' Deficit Current liabilities: 740,275 \$ 502,531 Accounts payable and accrued liabilities 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: - - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432)) Deficit accumulated during the development stage (4,472,953) (4,472,953)			1,290,017			1,286,840		
Current liabilities: 3740,275 \$ 502,531 Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: - - Common stock, par value \$.001; 100,000,000 shares - - authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stock	Total Assets	\$	3,390,014		\$	1,542,715		
Accounts payable and accrued liabilities \$ 740,275 \$ 502,531 Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: 50,005 - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627	Liabilities and Stockholders' Deficit							
Due to Goldner et al - current portion 802,748 607,000 Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Current liabilities:							
Due to related party - 72,862 Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Accounts payable and accrued liabilities	\$	740,275		\$	502,531		
Demand notes payable - 171,233 Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Due to Goldner et al - current portion		802,748			607,000		
Bank line of credit - 134,035 Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Due to related party		-			72,862		
Capital lease payable 661,559 - Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Demand notes payable		-			171,233		
Due to stockholders 229,345 107,481 Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Bank line of credit		-			134,035		
Total current liabilities 2,433,927 1,595,142 Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)			661,559			-		
Due to Goldner et al 348,477 971,200 Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Due to stockholders		229,345			107,481		
Deferred revenue 2,175,000 - Deferred gain 366,293 - Stockholders' equity: - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Total current liabilities		2,433,927			1,595,142		
Deferred gain 366,293 - Stockholders' equity: - Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Due to Goldner et al		348,477			971,200		
Stockholders' equity: Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Deferred revenue		2,175,000			-		
Common stock, par value \$.001; 100,000,000 shares authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Deferred gain		366,293			-		
authorized; 68,035,437 and 59,061,192 shares issued, respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Stockholders' equity:							
respectively 68,035 59,061 Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)								
Paid-in capital 4,149,240 3,639,074 Retained deficit (1,650,608) (273,432) Deficit accumulated during the development stage (4,472,953) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	authorized; 68,035,437 and 59,061,192 shares issued,							
Retained deficit (1,650,608)) (273,432) Deficit accumulated during the development stage (4,472,953)) (4,472,953) Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683)) (1,023,627)			68,035			59,061		
Deficit accumulated during the development stage (4,472,953	Paid-in capital		4,149,240			3,639,074		
Other comprehensive income (27,397) 24,623 Total Stockholders' deficit (1,933,683) (1,023,627)	Retained deficit	(1,650,608)	()
Total Stockholders' deficit (1,933,683) (1,023,627)	Deficit accumulated during the development stage	(4,472,953)	(4,472,953)
, , , , , , , , , , , , , , , , , , , ,	•	(27,397)		24,623		
Total Liabilities and Stockholders' Deficit \$ 3,390,014 \$ 1,542,715	Total Stockholders' deficit	(1,933,683)	(1,023,627)
	Total Liabilities and Stockholders' Deficit	\$	3,390,014		\$	1,542,715		

The accompanying notes are an integral part of these financial statements

GLOBETECH ENVIRONMENTAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the three months ended September 30,						
		2007				2006	
Revenue	\$	39,961		\$		-	
Cost of sales		5,806				-	
Gross profit		45,767				-	
Expenses:							
Consulting		78,219				58,643	
General and administrative		272,959				125,958	
Depreciation and amortization		32,994				4,730	
Total operating expenses		384,172				189,331	
Operating loss	(338,405)		(189,331)
Other Income (expense):							
Interest expense	(134,414)		(10,808)
Other income		7,988				742	
Total other income (expense)	(126,426)		(10,066)
Net loss	(464,831)		(199,397)
Foreign currency adjustment	(114,332)		(24,883)
Comprehensive loss	\$ (579,163)	\$	(224,280)
Loss per share, basic and diluted	\$ (0.01)	\$	(0.01)
Weighted average shares outstanding		67,536,807				53,086,023	

The accompanying notes are an integral part of these financial statements

GLOBETECH ENVIRONMENTAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the nine months ended September 30,						
		2007				2006	
Revenue	\$	86,703		\$		3,419	
Cost of sales		1,603				-	
Gross profit		85,100				3,419	
Expenses:							
Consulting		135,459				216,414	
Stock option expense		-				344,825	
General and administrative		966,354				292,019	
Depreciation and amortization		59,179				4,730	
Total operating expenses		1,160,992				857,988	
Operating loss	(1,075,892)		(854,569)
Other Income (expense):							
Interest expense	(324,881)		(23,429)
Other income		23,597				742	
Write-down of goodwill/assets		-			(474,821)
Total other income (expense)	(301,284)		(497,508)
Net loss	(1,377,176)		(1,352,077)
Foreign currency adjustment	(52,020)			2,509	
Comprehensive loss	\$ (1,429,196)		(1,349,568)
Loss per share, basic and diluted	\$ (0.02)	\$	(0.03)
Weighted average shares outstanding		65,906,879				53,086,023	

The accompanying notes are an integral part of these financial statements.

GLOBETECH ENVIRONMENTAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the nine months ended September 2007 2006						30,	
Cash flow from operating activities:								
Net loss	\$	(1,377,176)	\$	(1,352,077)
Adjustments to reconcile net loss to net cash								
used by operating activities:								
Depreciation and amortization			59,179				4,730	
Common stock issued for interest/services			29,974				182,724	
Stock based compensation			-				344,825	
Write down of assets			-				474,821	
Deferred gain			380,135				-	
		(907,888)		(344,977)
Change in operating assets and liabilities:								
Accounts Receivable		(42,164)			-	
Prepaid expenses		(482,543)			-	
Other receivable		(122,225)			-	
Accounts payable and accrued liabilities			237,743				138,007	
Net cash used in operating activities		(1,317,077)		(206,970)
Cash flow from financing activities:								
Proceeds from shareholder loan			121,863				16,968	
Proceeds from stock option exercise			-				29,625	
Sale of demand promissory note			-				171,232	
Payment to Goldner		(562,523)			-	
Related party loan			-				87,167	
Deferred revenue			2,175,000				-	
Payment of capital lease obligation		(38,711)			-	
Bank line of credit		(134,035)			126,870	
Shares issued on debenture conversion			-				65,000	
Proceeds from private placement			196,000				-	
Net cash provided by financing activities			1,757,594				496,862	
Cash flow from (used in) investing activities:								
Logmed Investment			-			(242,800)
Cash acquired in acquisition			-				492	
Patents/licenses/assets		(96,779)		(34,160)
Net cash used in investing activities		(96,779)		(276,468)
Effect of exchange rate on cash			118,760			(7,168)
Increase in cash			462,498				6,256	
Cash, beginning of period			71,628				1,219	
Cash, end of period	\$		534,126		\$		7,475	
Supplemental Information								
Cash paid for interest	\$		190,467		\$		-	

During the nine months ended September 30, 2007, 3,199,069 shares of common stock were issued to retire debt and accrued interest in the amount of \$191,944. A further 1,368,746 common shares were issued to a related party to retire debt and accrued interest of \$82,125. In September 2007, the Company settled an outstanding debt with a Director in the amount of \$24,931.50 by issuing 498,630 shares at a deemed price of \$.05 per share.

The accompanying notes are an integral part of these financial statements

GLOBETECH ENVIRONMENTAL, INC.

NOTES TO FINANCIAL STATEMENTS

THE PERIOD ENDED SEPTEMBER 30, 2007 AND 2006

NOTE 1 INTERIM FINANCIAL PRESENTATION

The interim consolidated financial statements of Globetech Environmental, Inc. (the Company) are prepared pursuant to the requirements for reporting on Form 10-QSB. These financial statements have not been audited by our independent registered public accounting firm. The December 31, 2006 balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The interim financial statements and notes thereto should be read in conjunction with the financial statements and notes included in the Company's Form 10-KSB for the year ended December 31, 2006. In the opinion of management, these interim financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim periods presented. The current period results of operations are not necessarily indicative of results, which ultimately will be reported for the full year ending December 31, 2007.

NOTE 2 GOING CONCERN

The accompanying financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assume that the Company will continue in operation for at least one year and will be able to realize its assets and discharge its liabilities in the normal course of operations.

Several conditions and events cast doubt about the Company s ability to continue as a going concern. The Company has incurred net losses of approximately \$6,123,561 for the period from April 7, 1997 (inception) to September 30, 2007, has a liquidity problem, and requires additional financing and or sales in order to finance its business activities on an ongoing basis. The Company is actively pursuing alternative financing and has had discussions with various third parties, although no firm commitments have been obtained.

The Company s ability to survive will depend on numerous factors including, but not limited to, the Company s receiving continued financial support, completing public equity financing, or generating profitable operations in the future.

These financial statements do not reflect adjustments that would be necessary if the Company were unable to continue as a going concern. While management believes that the actions already taken or planned, will mitigate the adverse conditions and events which raise doubt about the validity of the going concern assumption used in preparing these financial statements, there can be no assurance that these actions will be successful.

If the Company were unable to continue as a going concern , then substantial adjustments would be necessary to the carrying values of assets, the reported amounts of its liabilities, the reported revenues and expenses, and the balance sheet classifications used.

NOTE 3 - RECLASSIFICATIONS

Certain reclassifications have been made in the 2006 financial statements to conform with the 2007 presentation.

NOTE 4 COMMITMENTS

As of September 30, 2007, the Company maintained no formal offices in North America, but conducted its operations in space provided free of charge by the Company s principal officers. Currently, there are no outstanding debts owed by the company for the use of these facilities and there are no commitments for future use of the facilities. European operations are conducted from offices in Landsberg, Germany that are used pursuant to the terms of a month to month lease arrangement.

The Company entered into an employment agreement with Donald Sampson, effective as of March 1, 2005 for a period ending February 28, 2007, pursuant to which Mr. Sampson is employed as the Company s President and Chief Executive Officer. Effective March 1, 2007, the Company entered into a new two year employment agreement with Mr. Sampson. Under his new employment agreement, Mr. Sampson is entitled to a base salary of \$180,000 and a bonus equal to 2% of the EBITDA when it becomes positive, which will be paid quarterly. As of September 30, 2007 and 2006, \$0 and \$20,000 in salary has been paid and \$222,000 and \$70,000 has been accrued.

The Company entered into a consulting agreement with Theodor Hennig s professional corporation, effective as of September 27, 2005 for two years ending September 27, 2007, pursuant to which Mr. Hennig serves as the Company s Chief Financial Officer. Effective October 1, 2007, the Company entered into a new 15 month consulting agreement with Mr. Hennig s professional corporation. Under the new consulting agreement, Mr. Hennig is entitled to a monthly fee of CDN\$10,000 plus expenses and an annual bonus should certain EBITDA thresholds be met. As of September 30, 2007 and 2006, \$56,475 and \$16,666 in fees and expenses have been paid and \$141,746 and \$58,331 have been accrued.

Except for Mr. Sampson s employment agreement and Mr. Hennig s consulting agreement, the Company does not presently have employment agreements, or agreements relating to changes in control of the company, with any of its officers or employees.

The Company expects to enter into employment agreements with key employees, to implement comprehensive compensation arrangements with its officers and to adopt benefit plans in the future at the discretion of the Board of Directors to attract and retain officers and key employees.

Pursuant to the Tech-Rock LLC sales leaseback transaction discussed in Note 10 below, the Company has monthly lease payments of \$36,000 commencing in December 2007. These payments are intended to be offset by the leasing income generated by the units as they are placed in service.

Pursuant to the Med-Rock LLC sales leaseback transaction discussed in Note 10 below, the Company has monthly lease payments of \$36,000 commencing in December 2007. These payments are intended to be offset by the leasing income generated by the units as they are placed in service.

NOTE 5 - STOCKHOLDER ADVANCES

Stockholders of the Company have advanced the Company money in order to pay general and administrative expenses. As of September 30, 2007 and December 31 2006, the Company owed \$229,345 and \$107,481, respectively, relating to these advances. The stockholder loans have no specific repayment terms.

NOTE 6 DEMAND NOTES PAYABLE

The Company financed the 150,000 Euro Logmed down payment through a demand Promissory Note with Creative Financial Solutions, LLC of Arizona. The Note was for \$200,000 CDN with interest at 12% per annum. This note plus accrued interest of \$20,711.25 was converted to 3,199,069 shares at a deemed value of \$.06 per share effective January 31, 2007.

NOTE 7 RELATED PARTY PAYABLES

The Company financed the 50,000 Euro Logmed down payment and some working capital advances through a demand Promissory Note with the spouse of a Company officer. The Note was for \$90,000 CDN and bears interest at 12% per annum. This Note plus accrued interest of \$9,262.85 was converted to 1,368,746 shares at a deemed value of \$.06 per share effective January 31, 2007.

NOTE 8 MODIFICATION OF LOGMED PAYMENT TERMS

On March 17, 2006, Globetech Environmental, Inc. ("Globetech") entered into an agreement with Hans-Eberhardt Frenzel ("Frenzel"), Helmut Goldner ("Goldner"), Goldner Umwelt & Hygienetechnik GmbH ("GUH"), and Logmed Technologie GmbH ("Logmed Technologie") pursuant to which Globetech agreed to purchase certain rights, operations and technologies of Logmed Technologie and related persons.

On January 11, 2007, Globetech entered into an agreement with Goldner et al to modify the payment terms under their March 17, 2006 Purchase Agreement for the Logmed technologies. Pursuant to the terms of the original Purchase Agreement, a total of 500,002 Euro was due and payable to the Goldner Parties by December 31, 2006. Pursuant to the January 11, 2007 Amendment, the scheduled payment dates for the amounts originally due to the Goldner Parties on December 31, 2006 were revised to provide for a series of installment payments as follows:

50,000 Euro due January 17, 2007;

50,000 Euro due January 31, 2007 to Goldner;

15,000 Euro due January 31, 2007 to Frenzel;

18,332 Euro due August 31, 2007 to Frenzel payable in shares;

100,000 Euro due February 28, 2007;

100,000 Euro due March 31, 2007;

66,668 Euro due August 31, 2007 (paid August 31, 2007); and

100,000 Euro due September 30, 2007.

All deferred payments bear interest at 8% per annum. All contracted payments up to and including August 31, 2007 have been paid. The September 30, 2007 payment has not been made. The 100,000 Euro installment was deposited with Globetech s counsel in Germany and was to be released to Mr. Goldner provided certain requested conditions were satisfied. Management feels that Mr. Goldner has not been satisfactorily performing his obligations under the terms of our Purchase and Sale agreement and therefore some adjustments were required. The requested conditions were not satisfied and the funds were not transferred to Mr. Goldner. The Agreement was terminated in October 2007 as more fully described in the Subsequent events note below.

NOTE 9 - COMMON STOCK TRANSACTIONS

Effective January 31, 2007, the Company issued 1,368,746 shares to extinguish related party debt plus accrued interest due to a related party (see Note 7 above).

Effective January 31, 2007, the Company issued 3,199,069 shares to extinguish a demand note plus accrued interest (see Note 6 above).

In February 2007, the Company received \$150,000 pursuant to a private placement and issued 2,500,000 shares and 2,500,000 warrants to purchase shares at \$.12 for a period of two years.

In March 2007, the Company received \$11,000 pursuant to a private placement and issued 275,000 shares and 275,000 warrants to purchase shares at \$.08 for a period of two years.

In March 2007, the Company received \$20,000 pursuant to a private placement and issued 500,000 shares and 500,000 warrants to purchase shares at \$.08 for a period of two years.

In April 2007, the Company received \$15,000 pursuant to a private placement and issued 300,000 shares and 300,000 warrants to purchase shares at \$.10 for a period of two years.

In April, 2007, the Company issued 150,000 shares to extinguish a debt of \$15,000 owed to an arms-length party.

In June, 2007, the Company issued 182,800 shares to extinguish a debt of \$9,140 owed to an arms-length party.

In September 2007, the Company issued 498,630 shares to extinguish a debt of \$24,931.50 owed to a director.

In accordance with EITF 00-19, the issuance of the warrants described above is considered permanent equity and thus no value has been assigned to the warrants.

NOTE 10 SALE-LEASEBACK TRANSACTION

In May 2007, three Logmed units were sold to an American customer, Tech-Rock LLC, for \$1,500,000 cash pursuant to a sales/leaseback agreement. The first of these units is presently being refurbished and should be placed into operation within the next three months. The second unit is to be built and placed in operation as soon as possible. The third unit is a new Logmed machine that will be operated under lease in Abu Dhabi, United Arab Emirates. The UAE unit is being manufactured and is scheduled to be installed and operating in May, 2008.

The sales/leaseback agreement calls for monthly lease payments of \$12,000 per machine for a period of seven years.

On August 30, 2007, the Company entered into a Master Equipment Lease Agreement with MedRock LLC pursuant to which the Company sold to MedRock, for \$1,375,000, two Logmed II 500 machines that are currently being manufactured and expected to placed in service by December 1, 2007 and agreed to lease those machines with the intent of sub-leasing the machines to third-party end users. Pursuant to the Master Equipment Lease Agreement, the Company agreed to lease both of the Logmed machines for lease payments of \$13,000 per machine per month for a period of 120 months commencing on the earlier of (i) installation of each machine at the site of a third-party end user or (ii) December 1, 2007. These units are yet to be built and placed into operation.

The financial statements record the sales-leasebacks as essentially financing transactions. The leased assets and related lease obligations are recorded and the lease payments, related deferred gains and amortization are spread over the term of the leases.

NOTE 11 MEDIVAC JOINT VENTURE

In May 2007, the Company entered a joint venture with MediVac Limited of Australia. The joint venture agreement called for the incorporation of Logmed International Pty Ltd. which would own worldwide marketing rights for Globetech s Logmed machines and MediVac s Metamizer machines. The joint venture would have offices in Sydney Australia, Spokane and Landsberg, Germany and would be resourced to exploit sales opportunities around the globe.

NOTE 12 SUBSEQUENT EVENTS

Tech-Rock/BBR, Inc Master Equipment Lease

On November 1, 2007, the Company entered into a Master Equipment Lease Agreement with Tech-Rock LLC and BBR, Inc pursuant to which the Company sold for \$875,000, one Globetech GT500 machine that is expected to be placed in service by March 2008 and agreed to lease that machine with the intent of sub-leasing the machines to third-party end users. Pursuant to the Master Equipment Lease Agreement, the Company agreed to lease the machine for lease payments of \$14,600 per month for a period of 120 months commencing on the earlier of (i) installation of each machine at the site of a third-party end user or (ii) March 1, 2008.

MediVac Manufacturing and License Agreement

On December 1, 2007, the Company and MediVac Limited agreed to terminate their March 28, 2007 Joint Venture Agreement and to enter into Licensing Agreements. The agreements will permit each company to market the other s product line in stipulated geographic areas for a designated period of time. The Company will also assume the manufacturing of all of MediVac s Metamizer units sold by the Company and MediVac on a cost plus 20% basis.

Logmed / Goldner Agreement

Effective October 31, 2007, Helmut Goldner unilaterally terminated the Purchase and Sale Agreement pursuant to which the Company had previously acquired the rights to the intellectual property and patents pertaining to Logmed. Goldner s termination of the agreement was triggered by the Company withholding the 100,000 Euro payment that was due September 30, 2007. The Company withheld this payment in an effort to address the ongoing failure of Mr. Goldner to perform certain obligations under the agreement. The Company attempted to renegotiate the terms of the agreement to reflect the defaults by Mr. Golder but was unable to arrive at a satisfactory resolution. As a result of the termination, all Logmed intellectual property and patents reverted to Mr. Goldner, \$1,325,000 (900,000 Euro) in remaining payments to Goldner are eliminated and the Company will retain ownership and continue to operate Logmed Technologie GmbH as its European subsidiary and base of operations.

Item 2. Management s Discussion and Analysis or Plan of Operations

The following information should be read in conjunction with the Form 10-KSB filed for the year ended December 31, 2006, and other information regarding our financials performance for the period covered by this report, including, but not limited to, the financial statements included elsewhere in this report.

Forward-Looking Statements

This Management's Discussion and Analysis or Plan of Operations includes a number of forward-looking statements that reflect Management's current views with respect to future events and financial performance. Those statements include statements regarding the intent, belief or current expectations of the Company and members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by the Company in this report and in the Company's other reports filed with the Securities and Exchange Commission. Important factors currently unknown to Management could cause actual results to differ materially from those in forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. The Company believes that its assumptions are based upon reasonable data derived from and known about its business and operations and the business and operations of the Company. No assurances are made that actual results of operations or the results of the Company's future activities will not differ materially from its assumptions.

Overview and Developments During, and Following, the 2007 3rd Quarter

The Company s principal services and operations are comprised of the marketing, sales and leasing of its proprietary medical waste disinfection/sterilization units and the operation of several waste treatment facilities under contract.

Marketing efforts have identified numerous sales opportunities in Turkey, Greece, Australia, Romania, France, Canada and the US. The Company is also working on a substantial business opportunity in the People s Republic of China.

Globetech, and all its sales agents, attended the World Medica Fair Exposition in Dusseldorf, Germany in November for the third straight year. The Company also attended the Arab Health 2008 Medical Convention in Dubai.

The Company is also continuing with its efforts to have its technology certified for the destruction of Prions. A Logmed II is currently under construction which is to be placed in service in early 2008 and utilized in the Prion testing and certification process. Prions are proteins linked with mad-cow disease and other chronic wasting illnesses and the successful certification could lead to substantial opportunities in the handling of slaughterhouse wastes. The Company has applied for grants from the Alberta Government that are available to companies that can provide solutions to this expanding waste stream.

In May 2007, the Company entered a joint venture with MediVac Limited of Australia. The joint venture agreement called for the incorporation of Logmed International Pty Ltd. which would own worldwide marketing rights for Globetech's Logmed machines and MediVac's Metamizer

machines. The joint venture would have offices in Sydney Australia, Spokane and Landsberg, Germany and would be resourced to exploit sales opportunities around the globe. On December 1, 2007, the Company and MediVac Limited agreed to terminate their joint venture agreement and entered into Licensing Agreements. The agreements permit each company to market the other s product line in stipulated geographic areas for a designated period of time. The Company will also assume the manufacturing of all of MediVac s Metamizer units sold by the Company and MediVac on a cost plus 20% basis.

In May 2007 and August 2007, the Company sold Logmed machines and leased back those machines for sublease to third party users. Pursuant to the May 2007 sale/leaseback transaction (the TechRock Transaction), the Company sold two pre-owned Logmed machines and the rights with respect to a third Logmed machine, that is expected to be put in service during May 2008, for \$1,500,000 and agreed to lease each of the Logmed machines for monthly lease payments of \$12,000 per machine for a period of 84 months. Pursuant to the August 2007 sale/leaseback transaction (the MedRock Transaction), the Company sold two Logmed machines that are expected to be put in service during 2007 for \$1,375,000 and agreed to lease each of the Logmed machines for monthly lease payments of

\$13,000 per machine for a period of 120 months beginning on the earlier of installation of the machines for use by a third party or December 1, 2007. To date, none of the sold units have been placed into operation.

On November 1, 2007, the Company entered into a Master Equipment Lease Agreement with Tech-Rock LLC and BBR, Inc pursuant to which the Company sold for \$875,000, one Globetech GT500 machine that is expected to be placed in service by March 2008 and agreed to lease that machine with the intent of sub-leasing the machines to third-party end users. Pursuant to the Master Equipment Lease Agreement, the Company agreed to lease the machine for lease payments of \$14,600 per month for a period of 120 months commencing on the earlier of (i) installation of each machine at the site of a third-party end user or (ii) March 1, 2008.

Effective October 31, 2007, Helmut Goldner unilaterally terminated the Purchase and Sale Agreement pursuant to which the Company had previously acquired the rights to the intellectual property and patents pertaining to Logmed. Goldner s termination of the agreement was triggered by the Company withholding the 100,000 Euro payment that was due September 30, 2007. The Company withheld this payment in an effort to address the ongoing failure of Mr. Goldner to perform certain obligations under the agreement. The Company attempted to renegotiate the terms of the agreement to reflect the defaults by Mr. Golder but was unable to arrive at a satisfactory resolution. As a result of the termination, all Logmed intellectual property and patents reverted to Mr. Goldner, \$1,325,000 (900,000 Euro) in remaining payments to Goldner are eliminated and the Company will retain ownership and continue to operate Logmed Technologie GmbH as its European subsidiary and base of operations.

The Company has in 2007 applied for patents in the USA for its own GT Waste Sterilizer technology. The underlying work for this technology was completed over the last two years as it became evident that the Goldner intellectual property was not what it purported to be and that a better, proprietary system was required.

Critical Accounting Policies

The Company s discussion and analysis of its financial condition and results of operations are based upon the Company s financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The Company believes certain critical accounting policies affect its more significant judgments and estimates used in the preparation of its financial statements. A description of the Company s critical accounting policies is set forth in the Company s Form 10-KSB for the year ended December 31, 2006. As of, and for the quarter ended, September 30, 2007, there have been no material changes or updates to the Company s critical accounting policies. The sales-leaseback transactions have been booked in accordance with GAAP. The proceeds of sale, less accrued costs of production were recorded as deferred gains which will be brought into income over the term of the leases. The assets are recorded as capital leases with the offsetting liabilities recorded as lease obligations in long term debt.

Results of Operations

Revenues. The Company recorded operating revenues of \$86,703 and \$3,419 during the nine months ended September 30, 2007 and 2006 respectively. Revenues during the first nine months of 2007 were attributable to the operation conducted at the Halle and Utrecht medical facilities and the reporting of the portion of the deferred gain on the sale/leaseback of two Logmed units placed in service during the third quarter of 2007 pursuant to the Tech-Rock transaction.

Operating Expenses. Operating expenses totaled \$1,160,992 during the nine months ended September 30, 2007 as compared to \$857,988 during the same period ended September 30, 2006. Operating expenses consisted principally of salary and consulting fees and general corporate overhead. The increase in operating expenses during the 2007 period related principally to the increased operations relating to the marketing of the Company s GT Wastes Sterilizer technology, including the costs of the Landsberg, Germany office, travel related to the establishment of the MediVac joint venture and development costs pertaining to the Logmed upgrading and redesign.

Other Income (Expense). The Company reported other expense, net of other income, of \$301,284 during the nine months ended September 30, 2007 as compared to expenses of \$497,508 during the 2006 period. Net other expense during the 2007 period consisted of interest, financing and miscellaneous charges. The Company had written off \$474,821 in goodwill in 2006 pertaining to the amount by which the Logmed Technologie GmbH share purchase price exceeded the net underlying net asset value. The increased interest expense relates to various financing costs including leasing, German line of credit, and loan interest.

Liquidity and Capital Resources

Cash and Working Capital Position

The Company had a cash balance of \$534,126 at September 30, 2007 and \$71,628 at December 31, 2006 and a deficit in working capital of \$1,181,751 at September 30, 2007 and \$1,452,396 at December 31, 2006.

The Company has been dependent upon financing provided in the form of private placements or loans from its principal officers, directors and stockholders and from sale/leaseback transactions to support its ongoing operations. The Company expects, in the near term, to continue to be dependent upon financing provided by its principal officers, directors and stockholders and from sale/leaseback transactions and the sale of securities to, or financing provided by, third parties. Except as noted herein, the Company has no commitments from its principal officers, directors and stockholders or third parties to provide financing. The current business plan and budget reflect sufficient sales by year-end to obviate the need for additional external financing.

The significant monthly lease payments due pursuant to the sales-leaseback transactions place a substantial burden on the cash resources of the Company and it is essential that the related units are built and placed into operation soon in order to generate sufficient cash flow to meet these obligations.

Included in the Company s working capital deficit at September 30, 2007 were stockholders loans totaling \$229,345 and the current amount due to H. Goldner of \$802,748. Subsequent to September 30, 2007, the Goldner acquisition was terminated and all related assets were returned to Goldner and liabilities extinguished.

Cash Flows

The Company utilized \$1,317,077 in cash for operations during the first nine months of 2007 as compared to \$206,970 used in operations during the 2006 period. The increase in cash used in operations in the 2007 period was principally attributable to payingore expenses in cash, decreases in non-cash expenses in the current period and an increase in pre-paid expenses in the current period.

Investing activities used \$96,779 of cash during the first nine months of 2007 as compared to \$276,468 used in investing activities during the 2006 period. Cash used in investing activities during the 2006 quarter related principally to the Logmed technology acquisition.

Financing activities provided \$1,757,594 of cash to the Company during the first nine months of 2007 as compared to \$496,862 provided in the 2006 period. In 2007, cash provided by financing activities was largely attributable to \$1,500,000 sale proceeds from the TechRock sale/leaseback transaction and \$196,000 raised in private placements. In 2006, cash provided by financing activities was attributable to the sale of demand promissory notes in the amount of \$171,232, exercise of stock options in the amount of \$29,625 and loans of \$87,167.

Long-Term Debt

Long-term debt totaled \$2,889,770 at September 30, 2007 as compared to \$971,200 at December 31, 2006. Long-term debt at September 30, 2007 consisted of \$348,477 with respect to the Logmed Technologie acquisition, \$1,500,000 of deferred revenue from the Tech-Rock LLC sale/leaseback, \$675,000 of deferred revenue from the MedRock sale/leaseback and \$366,293 of deferred gain related to the sale of two Logmed units. Subsequent to September 30, 2007, the Logmed Technologie acquisition was terminated, relieving the Company of long-term debt relating to that acquisition.

Financial Commitments and Requirements

At September 30, 2007, the Company s principal financial commitments and requirements related to funding operational deficits, overhead and purchase and operational payments relating to the March 2006 acquisition of Logmed Technologie GmbH and lease payments relating to sale/leaseback transactions with Tech-Rock LLC and MedRock LLC. As noted, the Logmed Technologie acquisition was terminated subsequent to September 30, 2007 relieving the Company of purchase payment obligations thereunder.

The Company has monthly lease payments of \$36,000 due to Tech-Rock LLC pursuant to the sale leaseback agreement and \$26,000 due monthly to Med-Rock LLC.

Inflation

Inflation has historically not had a material effect on the Company s operations.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements.

Item 3. Controls and Procedures

The Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO) are responsible for establishing and maintaining disclosure controls and procedures for the Company.

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon the evaluation, the Company's CEO and CFO concluded that, as of the end of the period, the Company's disclosure controls and procedures were effective in timely alerting management to material information relating to the Company required to be included in the reports that the Company files and submits pursuant to the Exchange Act.

During the quarter ended September 30, 2007, there were no significant changes in our internal controls over financial reporting that materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

PART II OTHER INFORMATION

Item 6. Exhibits

Exhibit	
Number	Title of Document
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Globetech Environmental, Inc.

Date: March 13, 2008 By: /s/ Donald Sampson

Donald Sampson President and Director (Principal Executive Officer)

Date: March 13, 2008 By: /s/ Theodor Hennig

Theodor Hennig

Chief Financial Officer, Secretary and Director

(Principal Financial Officer)